NEW YORK (360Dx) – Chembio Diagnostics said today that it has entered into an agreement with Perseus Science Group to advance the development of a diagnostic test for mild traumatic brain injury, or concussion.

Under the terms of the agreement, Medford, New York-based Chembio will receive funding of an undisclosed amount from Perseus, subject to satisfying certain milestones, to advance the development of a quantitative point-of-care test for concussion that combines Perseus’ concussion biomarker with Chembio's DPP platform, a chromatographic immunoassay.